Live Chat
Today's Hours: 10:00am - 6:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Steven M. Donn, Sunil K. Sinha, editors.
    Contents:
    Section I. Lung development and maldevelopment
    Section II. Principles of mechanical ventilation
    Section III. Procedures and techniques
    Section IV. Monitoring the ventilated patient
    Section V. Noninvasive ventilatory techniques
    Section VI. Ventilatory modes and modalities
    Section VII. High-frequency ventilation
    Section VIII. Commonly used neonatal ventilators
    Section IX. Adjunctive therapies
    Section X. Management of common neonatal respiratory diseases
    Section XI. Bronchopulmonary dyplasia
    Section XII. Complications associated with mechanical ventilation
    Section XIII. Other considerations
    Section XIV. Ethical and legal considerations
    Section XV. Research, quality, and the literature
    Section XVI. Ventilatory case studies
    Appendix
    Index.
    Digital Access Springer 2017
  • Article
    Cunha-Vaz JG, Reis Fonseca J, Hagenouw JR.
    Br J Ophthalmol. 1977 Jun;61(6):399-404.
    In order to assess the effect of cyclandelate on the abnormal permeability of the blood-retinal barrier which occurs in diabetic patients before any other lesions are apparent in the retina a well-controlled, double blind, and paired trial was carried out in 22 patients. The treatments were randomised. The permeability of the blood-retinal barrier was assessed by vitreous fluorophotometry. Each patient was examined before being involved in the trial and then another 3 times with 1 month's interval. The total duration of treatment was 3 months. The results showed that the breakdown of the blood-retinal barrier as evidenced by the degree of abnormal fluorescein penetration into the vitreous suffered a significant decrease in the diabetic patients treated with cyclandelate when compared to the patients submitted to placebo administration, and this effect is particularly apparent in the third month of treatment.
    Digital Access Access Options